Neuronetics Enhances TrakStar® Cloud Patient Data Management System to Maximize Physician Efficiencies

Rhea-AI Summary

Neuronetics (NASDAQ: STIM) announced significant upgrades to its TrakStar Cloud system, aimed at enhancing clinician productivity and patient management. The HIPAA-compliant platform improvements include advanced Outcomes Reporting, comprehensive Medication Assignments, on-demand Training Videos, a Patient Leads Tracker, and new Patient Rating Scales. These updates are designed to streamline administrative tasks for practices treating patients with Major Depressive Disorder (MDD). The enhancements are immediately available to all U.S.-based TrakStar customers.

Positive

• TrakStar Cloud system upgrades enhance clinician productivity.
• New features improve patient management for MDD treatment.
• Immediate availability of updates to U.S. customers.

Negative

• None.

Technology advancements to improve clinician productivity and optimize time spent with patients

MALVERN, Pa., March 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced upgrades to its TrakStar^® Cloud system, a HIPAA-compliant, proprietary software that manages NeuroStar Advanced Therapy patient data. The latest improvements, made with insights from practicing clinicians, are designed to optimize time spent with patients while limiting time spent in practices on paperwork and other administrative tasks.

The TrakStar Cloud patient data management system allows physicians to proactively manage, easily track and reliably report on data for people suffering from Major Depressive Disorder (MDD) who are being treated with NeuroStar. The platform enhancements have been made to positively impact productivity, safety and practice marketing. Some of the new feature highlights include:

• Outcomes Reporting tool now provides more reporting options, including by demographics and treatment protocol.
• Medication Assignments now accommodates more options when reporting medication frequency and dosage.
• Training Videos are now easily available anytime within the TrakStar platform.
• Patient Leads Tracker to enable more efficient follow-up and scheduling for prospective patients.
• Additional Patient Rating Scales including Quick Inventory of Depressive Symptomology (QIDS-SR), Inventory of Depressive Symptomology (IDS-SR) and Generalized Anxiety Disorder Assessment (GAD-7).
  

“Listening to what our NeuroStar providers need allows us to work alongside clinicians to ensure they have the most advanced tools and technology to continually improve patient care,” said Greg Harper, Vice President, Research & Development and Clinical at Neuronetics. “We’re committed to innovations that enable practices to operate more efficiently, as we work toward our shared mission to help those struggling with depression.”

The TrakStar Cloud updates will be available immediately for all U.S.-based TrakStar Cloud customers.

Since receiving FDA clearance in 2008 as a safe and effective option for adult patients MDD, Neuronetics has been a trailblazer in treatment of depression, and its NeuroStar system is the number one choice of TMS doctors. Neuronetics also recently announced FDA clearance for its TouchStar treatment, a three-minute intermittent theta burst (iTBS) protocol, administered with the NeuroStar system’s patented Contact Sensing technology. Visit www.NeuroStar.com for more information.

About Neuronetics
Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar^® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Visit NeuroStar.com for safety information and indications for use. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.

Media Contact:
Chelsey Manko
Vault Communications
610-455-2778
cmanko@vaultcommunications.com

 

FAQ

What are the recent upgrades to Neuronetics' TrakStar Cloud system?

Neuronetics upgraded its TrakStar Cloud system with features for improved outcomes reporting, medication assignments, training videos, a patient leads tracker, and additional patient rating scales.

How do the TrakStar Cloud updates benefit clinicians?

The updates are designed to optimize clinician productivity by reducing time spent on administrative tasks while enhancing patient management.

When will the TrakStar Cloud updates be available?

The upgrades are available immediately for all U.S.-based TrakStar Cloud customers.

What does the TrakStar Cloud system manage?

The TrakStar Cloud system manages patient data for individuals suffering from Major Depressive Disorder (MDD) being treated with NeuroStar.

What is the significance of the TrakStar Cloud system for psychiatric care?

The TrakStar Cloud system is crucial for efficiently managing treatment data, thereby improving care for patients with psychiatric disorders.